A federal appeals court said Regeneron Pharmaceuticals Inc. and Sanofi SA can continue selling their cholesterol drug, Praluent, while they appeal the order, according to a Reuters article.
A judge previously blocked sales of the drug after Amgen won a trial wherein it accused them of patent infringement. The order would have taken effect on Feb. 21.
Regeneron general counsel Joseph LaRosa said in a statement the company would continue to defend its case through the appeal process.
Read the full story